PV Bulletin
PvBulletin
Home /Regulators/FDA Public Notification: Tawon Liar Contains Hidden Drug Ingredients
RegulatorsFDAUnited States

FDA Public Notification: Tawon Liar Contains Hidden Drug Ingredients

FDA advises consumers not to purchase or use Tawon Liar due to undisclosed active ingredients including tapentadol, dexamethasone, and meloxicam.

PV Impact Brief

Urgency: HighConfidence: high
Relevant for
Regulatory Intelligence LeadSignal Management Lead
Processes impacted
Signal ManagementLabeling
Action needed

Review product inventory for Tawon Liar; report any adverse events to FDA MedWatch; consider adding product to signal monitoring list; ensure labeling compliance checks for similar products.

Owner

Regulatory Intelligence Lead

Review cadence

as needed

Regulatory action details

Action type
Public Notification
Publication date
2026-05-29
Safety issue
Contains hidden drug ingredients which may cause serious side effects or interactions.

Affected products

  • Tawon Liar

PV internal implications

Monitor for adverse events from unapproved drug ingredients.

View regulator source

Evidence and confidence

Confidence: highSource updated: May 29, 2026

Full briefing

What changed

FDA updated its public notification regarding Tawon Liar on May 29, 2026, adding detection of tapentadol, dexamethasone, and meloxicam. Previous notifications in 2023 and 2022 reported meloxicam, ketorolac, and dexamethasone.

Why it matters

The product contains undeclared active pharmaceutical ingredients, including a controlled opioid, an NSAID, and a corticosteroid, which can cause serious adverse reactions, drug interactions, and have abuse potential.

Practical implication

Review product inventory for Tawon Liar; report any adverse events to FDA MedWatch; consider adding product to signal monitoring list; ensure labeling compliance checks for similar products.

Related updates for your role

RegulatorsMedicines and Healthcare products Regulatory Agency (MHRA)United Kingdom

MHRA Largest Seizure of Unlicensed Weight Loss Medicines

Regulatory action
Enforcement Action / Public Safety Alert
Unlicensed weight loss medicines · Illicit manufacturing operation (unnamed)
Relevant for
Regulatory Intelligence LeadSignal Management Lead
Action needed

Review adverse event reports for potential links to counterfeit weight loss medicines; check product supply chain for unlicensed sources.

Process impact
Signal ManagementLabeling
SOP impact

2 SOPs may need review

Urgency: HighConfidence: high
Read impact brief
RegulatorsFDAUnited States

Covidien MonaTherm General Purpose Temperature Probe Recall (Class 2)

Regulatory action
Recall
Shiley Cuffed Fenestrated Adult Tracheostomy Tube · Covidien (Medtronic)
Lot/batch: Z-2261-2026
Relevant for
Regulatory Intelligence LeadSignal Management Lead
Action needed

Immediately quarantine and return unused MonaTherm probes from affected lots; review patient records for potential exposure and adverse events.

Process impact
Signal ManagementLabeling
SOP impact

2 SOPs may need review

Urgency: HighConfidence: high
Read impact brief
AI/GxPFdaUnited Kingdom

MHRA updates SaMD/AIaMD guidance, highlighting PCCP and transparency principles

Relevant for
Signal Management LeadRegulatory Intelligence LeadMedical Device Vigilance LeadPV Quality Lead+2 more
Action needed

Ask the safety/device vigilance and PV CSV leads to: (1) confirm whether any marketed/fielded SaMD/AIaMD uses adaptive ML or planned updates that would fit a PCCP-like approach; (2) review current change-control SOPs and technical documentation to ensure change governance and transparency artifacts are captured and retrievable; (3) verify post-market/vigilance processes explicitly account for algorithm updates (e.g., monitoring after updates, escalation criteria).

Process impact
Risk ManagementDevice VigilanceInspection Readiness
SOP impact

5 SOPs may need review

Urgency: HighConfidence: medium
Read impact brief
RegulatorsEuropean Medicines Agency (EMA)European Union

EMA ETF recommends updating COVID-19 vaccines to target XFG variant for 2026/2027 campaign

Regulatory action
Regulatory Recommendation / Public Health Communication
COVID-19 vaccines · Marketing authorisation holders (various)
Relevant for
Regulatory Intelligence LeadSignal Management Lead
Action needed

Marketing authorisation holders should prepare to update their COVID-19 vaccines to target the XFG variant for the upcoming campaign; monitor for further regulatory guidance and prepare for potential strain change submissions.

Process impact
Signal ManagementLabeling
SOP impact

2 SOPs may need review

Urgency: MonitorConfidence: high
Read impact brief